ClinicalTrials.gg
Active, not recruitingNCT02932150Updated Nov 12, 2026

Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

A Phase 2 interventional study of TAF and Placebo in Chronic Hepatitis B, sponsored by Gilead Sciences. Active, not recruiting at 39 sites in 8 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Updated Nov 12, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic — 5 open to participants now, 10 under way, 1 of them phase 3. tenofovir alafenamide · Hepatitis B, Chronic.

Planned enrollment
12th of 26
150 · median 124
Started
2016
with 1 other
Phase 2
4 of 26
none open now
Registered
3rd of 26
by date
Lead sponsor
5 of 26
Gilead Sciences

Among the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, this one is the 12th largest by planned enrollment, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 3rd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

5 of the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tenofovir alafenamide

tenofovir alafenamide: first FDA approval 2015 (GENVOYA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

Keywords

  • CHB
  • HBV
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

  • Males and non-pregnant, non-lactating females
  • Weight at screening as follows:

    • Cohort 1 = ≥ 35 kg (≥ 77 lbs)
    • Cohort 2 Group 1 = ≥ 25 kg (≥ 55 lbs)
    • Cohort 2 Group 2 = ≥ 14 kg to \< 25 kg (≥ 30 lbs to \<55 lbs)
    • Cohort 2 Group 3 = ≥ 10 kg to \< 14 kg (≥ 22 lbs to \< 30 lbs) or

      • 14 kg to \< 25 kg (≥ 30 lbs to \< 55 lbs)
  • Willing and able to provide written /assent (child and parent/legal guardian)
  • Documented evidence of CHB (eg, -positive for ≥ 6 months)
  • HBeAg-positive, or HBeAg-negative, chronic HBV infection with all of the following:

    • Screening HBV DNA ≥ 2 × 10\^4 IU/mL
    • Screening serum > 45 U/L (> 1.5 × : 30 U/L) and ≤ 10 × ULN (by central laboratory range)
  • Treatment-naive or treatment-experienced will be eligible for enrollment.
  • Estimated (CLCr) ≥ 80 mL/min/1.73m\^2 (using the Schwartz formula)
  • Normal

Key Exclusion criteria:

  • Females who are pregnant or breastfeeding
  • Males and females of who are unwilling to use an "effective", protocol-specified method(s) of during the study.
  • Coinfection with virus (HCV), , or hepatitis D virus (HDV)
  • Evidence of hepatocellular carcinoma (Note: if screening alpha-fetoprotein (AFP) is \< 50 ng/mL no imaging study is needed; however, if the screening AFP is > 50 ng/mL an imaging study is required)
  • Any history of, or current evidence of, clinical hepatic decompensation
  • Abnormal hematological and biochemical parameters
  • Chronic liver disease of non-HBV etiology (e.g., hemochromatosis, alpha-1 antitrypsin deficiency, cholangitis)
  • Received solid organ or bone marrow transplant
  • Currently receiving therapy with immunomodulators (eg, ), or
  • Significant renal, cardiovascular, pulmonary, or neurological disease in the opinion of the Investigator
  • within the 5 years prior to screening. Individuals under evaluation for possible malignancy are not eligible.
  • Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    TAF (Cohort 1)

    Participants (12 to \< 18 years) weighing ≥ 35 kg will receive TAF 25 mg tablet for 24 weeks

    Drug: TAF

  • Placebo comparator
    Placebo (Cohort 1)

    Participants (12 to \< 18 years) weighing ≥ 35 kg will receive placebo tablet for 24 weeks

    Drug: Placebo

  • Experimental
    TAF (Cohort 2 Group 1)

    Participants (6 to \< 12 years) weighing ≥ 25 kg will receive TAF 25 mg tablet for 24 weeks

    Drug: TAF

  • Experimental
    TAF (Cohort 2 Group 2)

    Participants (6 to \< 12 years) weighing ≥ 14 kg to \< 25 kg will receive TAF 15 mg oral granules for 24 weeks

    Drug: TAF

  • Experimental
    TAF (Cohort 2 Group 3)

    Participants (2 to \< 6 years) will receive TAF for 24 weeks as follows: * weight ≥ 10 kg to \< 14 kg (7.5 mg oral granules) * weight ≥ 14 kg to \< 25 kg (15 mg oral granules) The study has reopened and recruitment is initiated only for this cohort for ≥ 10 to \< 14 kg at this time.

    Drug: TAF

  • Placebo comparator
    Cohort 2 Placebo

    Participants will receive matching placebo of TAF (tablet or oral granules) for 24 weeks.

    Drug: Placebo

  • Experimental
    Open-Label TAF

    Following 24 weeks of blinded randomized treatment, participants will be eligible to participate in an open-label extension phase to receive TAF for an additional 216 weeks.

    Drug: TAF

Interventions

  • DrugTAF

    Administered orally once daily

  • DrugPlacebo

    Administered orally once daily

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Serious Adverse Events (SAEs) at Week 24

    Time frame: Week 24

  2. Incidence of Treatment-Emergent Adverse Events (AEs) at Week 24

    Time frame: Week 24

  3. Percentage of participants with plasma HBV DNA < 20 IU/mL at Week 24

    Time frame: Week 24

  4. PK Parameter: AUCtau of TAF for participants from Cohort 2 Part A

    AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

    Time frame: Predose, 15 minutes, 30 minutes, 1, 1.5, 2, 3, 4, 5, and 8 hours postdose at Week 4 or 8 or 12

Secondary outcomes

  1. Percentage of participants experiencing graded laboratory abnormalities

    Time frame: Weeks 24, 48, 96, and 240

  2. Development as measured by Tanner Stage Assessment

    Time frame: Weeks 24, 48, 96, and 240

  3. Percentage change from baseline in bone mineral density (BMD) of whole body (minus head) by dual imaging x-ray absorptiometry (DXA)

    Time frame: Baseline; Weeks 24, 48, 96, and 240

  4. Percentage change from baseline in BMD of lumbar spine by DXA

    Time frame: Baseline; Weeks 24, 48, 96, and 240

  5. Change from baseline in serum creatinine

    Time frame: Baseline; Weeks 4, 8, 12, 24, 48, 96, and 240

  6. Change from baseline in estimated glomerular filtration rate (eGFR) by the Schwartz formula

    Time frame: Baseline; Weeks 24, 48, 96, and 240

  7. Incidence of treatment-emergent SAEs in participants treated with TAF or placebo for 24 weeks followed by open-label TAF at Weeks 48, 96 and 240

    Time frame: Weeks 48, 96, and 240

  8. Incidence of treatment-emergentAEs in participants treated with TAF or placebo for 24 weeks followed by open-label TAF at Weeks 48, 96 and 240

    Time frame: Weeks 48, 96, and 240

  9. Change from baseline in retinol-binding protein to creatine ratio at Weeks 4, 8, 12, 24, and 48

    Time frame: Baseline; Weeks 4, 8, 12, 24, and 48

  10. Change from baseline in beta-2-microglobulin to creatine ratio at Weeks 4, 8, 12, 24, and 48

    Time frame: Baseline; Weeks 4, 8, 12, 24, and 48

  11. Change from baseline in glucose at Weeks 4, 8, 12, 24, and 48

    Time frame: Baseline; Weeks 4, 8, 12, 24, and 48

  12. Change from baseline in phosphate at Weeks 4, 8, 12, 24, and 48

    Time frame: Baseline; Weeks 4, 8, 12, 24, and 48

  13. Percentage of participants with plasma HBV DNA < 20 IU/mL at Weeks 48, 96, and 240

    Time frame: Weeks 48, 96, and 240

  14. Proportion of participants with plasma HBV DNA < 20 IU/mL (target not detected) at Weeks 24, 48, 96, and 240

    Time frame: Weeks 24, 48, 96, and 240

  15. Percentage of participants with alanine aminotransferase (ALT) normalization at Weeks 24, 48, 96, and 240

    Time frame: Weeks 24, 48, 96, and 240

  16. Composite endpoint of percentage of participants with ALT normalization and HBV DNA < 20 IU/mL at Weeks 24, 48, 96 and 240

    Time frame: Weeks 24, 48, 96 and 240

  17. Change from baseline in fibrosis as assessed by FibroTest at Weeks 24, 48, 96, and 240

    Time frame: Baseline; Weeks 24, 48, 96, and 240

  18. Percentage of participants with hepatitis B e antigen (HBeAg) loss and seroconversion to anti-HBe (HBeAG-positive participants only) at Weeks 24, 48, 96, and 240

    Time frame: Weeks 24, 48, 96, and 240

  19. Percentage of participants with composite endpoint of HBeAg seroconversion and HBV DNA < 20 IU/mL at Weeks 24, 48, 96, and 240 (in HBeAg-positive participants only)

    Time frame: Weeks 24, 48, 96, and 240

  20. Percentage of participants with composite endpoint of ALT normalization, HBeAg seroconversion and HBV DNA < 20 IU/mL at Weeks 24, 48, 96, and 240 (in HBeAg-positive participants only)

    Time frame: Weeks 24, 48, 96, and 240

  21. Percentage of participants with hepatitis B surface antigen (HBsAg) loss and seroconversion to anti-HBs at Weeks 24, 48, 96, and 240

    Time frame: Weeks 24, 48, 96, and 240

  22. Percentage of participants with qHBsAg log10 IU/mL at Weeks 24, 48, 96, and 240

    Time frame: Weeks 24, 48, 96, and 240

  23. Incidence of resistance mutations at Weeks 24, 48, 96, and 240

    Time frame: Weeks 24, 48, 96, and 240

  24. Acceptability of study drug

    To assess acceptability of study drug, the investigator will ask participants if they were able to taste the medication on a scale of 1-5, how much they like the taste of the medication (1 = dislike very much to 5 = like very much).

    Time frame: Baseline; Weeks 4, 24, and 36

  25. Palatability of study drug

    To assess palatability of study drug, the investigator will ask participants on a scale of 0-3 how easy it was to swallow the pill (0 = poor to 3 = excellent).

    Time frame: Baseline; Weeks 4, 24, and 36

  26. PK Parameter: AUCtau of tenofovir (TFV)

    AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

    Time frame: Predose, 15 minutes, 30 minutes, 1, 1.5, 2, 3, 4, 5, and 8 hours postdose at Week 4 or 8 (Cohort 1), and Week 4, 8, or 12 (Cohort 2)

  27. PK Parameter: AUClast of TAF and TFV

    AUClast is defined as the concentration of drug from time zero to the last observable concentration.

    Time frame: Predose, 15 minutes, 30 minutes, 1, 1.5, 2, 3, 4, 5, and 8 hours postdose at Week 4 or 8 (Cohort 1), and Week 4, 8, or 12 (Cohort 2)

  28. PK Parameter: Ctau of TFV

    Ctau is defined as the observed drug concentration at the end of the dosing interval.

    Time frame: Predose, 15 minutes, 30 minutes, 1, 1.5, 2, 3, 4, 5, and 8 hours postdose at Week 4 or 8 (Cohort 1), and Week 4, 8, or 12 (Cohort 2)

  29. PK Parameter: Cmax of TAF and TFV

    Cmax is defined as the maximum observed concentration of drug.

    Time frame: Predose, 15 minutes, 30 minutes, 1, 1.5, 2, 3, 4, 5, and 8 hours postdose at Week 4 or 8 (Cohort 1), and Week 4, 8, or 12 (Cohort 2)

  30. PK Parameter: Clast of TAF and TFV

    Clast is defined as the last observable concentration of drug.

    Time frame: Predose, 15 minutes, 30 minutes, 1, 1.5, 2, 3, 4, 5, and 8 hours postdose at Week 4 or 8 (Cohort 1), and Week 4, 8, or 12 (Cohort 2)

  31. PK Parameter: Tmax of TAF and TFV

    Tmax is defined as the time of Cmax (the maximum concentration of drug).

    Time frame: Predose, 15 minutes, 30 minutes, 1, 1.5, 2, 3, 4, 5, and 8 hours postdose at Week 4 or 8 (Cohort 1), and Week 4, 8, or 12 (Cohort 2)

  32. PK Parameter: Tlast of TAF and TFV

    Tlast is defined as the time (observed time point) of Clast.

    Time frame: Predose, 15 minutes, 30 minutes, 1, 1.5, 2, 3, 4, 5, and 8 hours postdose at Week 4 or 8 (Cohort 1), and Week 4, 8, or 12 (Cohort 2)

  33. PK Parameter: λz of TAF and TFV

    λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.

    Time frame: Predose, 15 minutes, 30 minutes, 1, 1.5, 2, 3, 4, 5, and 8 hours postdose at Week 4 or 8 (Cohort 1), and Week 4, 8, or 12 (Cohort 2)

  34. PK Parameter: CL/F of TAF and TFV

    CL/F is defined as the apparent oral clearance following administration of the drug.

    Time frame: Predose, 15 minutes, 30 minutes, 1, 1.5, 2, 3, 4, 5, and 8 hours postdose at Week 4 or 8 (Cohort 1), and Week 4, 8, or 12 (Cohort 2)

  35. PK Parameter: Vz/F of TAF and TFV

    Vz/F is defined as the apparent volume of distribution of the drug.

    Time frame: Predose, 15 minutes, 30 minutes, 1, 1.5, 2, 3, 4, 5, and 8 hours postdose at Week 4 or 8 (Cohort 1), and Week 4, 8, or 12 (Cohort 2)

  36. PK Parameter: t1/2 of TAF and TFV

    t1/2 is defined as the estimate of the terminal elimination half-life of the drug.

    Time frame: Predose, 15 minutes, 30 minutes, 1, 1.5, 2, 3, 4, 5, and 8 hours postdose at Week 4 or 8 (Cohort 1), and Week 4, 8, or 12 (Cohort 2)

07

Study locations

39 sites
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Oct 2026, 119 months.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 119 months is above that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2016
First posted
Oct 13, 2016
StartActual
Nov 2016
Primary completionActual
Oct 27, 2026was Sep 2026
CompletionEst.
Oct 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Oct 27, 2026 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Sep 2026→Oct 27, 2026 (now actual)
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02932150
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Oct 13, 2016
Start date
Nov 2016
Primary completion
Oct 27, 2026
Completion
Oct 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir alafenamide

Start the discussion